BCL2 and leukemia: Compound 24 (Figure 8) was the one with the ability to stabilize both G4s in a FRET melting assay (ΔTm = 12.8 °C for c-MYC G4 and 6.7 °C for BCL2 G4) and to downregulate c-MYC and BCL2 expression by 66% and 67%, respectively, after the treatment of Jurkat cells (human leukemia cell line) with 25 μM of the compound for 24 h.